Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 8/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.35 |
| ▸ | PDE4A | P27815 | 6/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660730 | 0.78 | PDE4B (0.45) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL14042205 | 0.75 | PDE4B (0.38) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL10102177 | 0.69 | SMYD2 (0.37) | KMT2AMEN1ALDH1A1GAAKDM4E | |
| SCHEMBL10413533 | 0.67 | CYP1A2 (0.61) | PDE4BKMT2AMEN1PDE4DALDH1A1 | |
| SCHEMBL10102186 | 0.67 | MAPK14 (0.37) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL3924278 | 0.63 | CA12 (0.73) | PDE4BKMT2APDE4DPDE4APDE4C | |
| SCHEMBL4786846 | 0.63 | PDE4B (0.48) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL659838 | 0.63 | PDE4B (0.48) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL10107127 | 0.63 | PDE4B (0.48) | PDE4BKMT2AMEN1PDE4DPDE4A | |
| SCHEMBL16506070 | 0.63 | RORC (0.50) | PDE4BKMT2AMEN1PDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536157-B2 | Non-steroidal compounds | THE UNIVERSITY OF MELBOURNE (AU) | 2013-09-17 | — | — | US | disclosed |
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | THE UNIVERSITY OF MELBOURNE of ROYAL PARADE PARKVILLE (AU) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046255-A1 | NON-STEROIDAL COMPOUNDS | PTGES2, PTGES, PTGES3 | PDE4B 823/4885KMT2A 4832/4885MEN1 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.